findmyKOL
Clinical trialNCT00024570CompletedPhase 1/PHASE2Interventional

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

SponsorINSYS Therapeutics IncEnrollment60Anaplastic AstrocytomaGlioblastoma MultiformeMalignant GliomaMixed Oligoastrocytoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells. IL13-PE38QQR will be infused in two courses of 96 hours each, eight weeks apart, directly into the malignant brain tumors of patients to determine the dose of drug these patients can tolerate. After that, the selected dose will be studied to give an estimate of the response rate, response duration, time to response, and survival after infusing that dose of IL13-PE38QQR into the recurrent malignant glioma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham

    Birmingham, Alabama, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, United States

  • Emory University

    Atlanta, Georgia, United States

  • the Johns Hopkins University

    Baltimore, Maryland, United States

  • Henry Ford Health Systems

    Detroit, Michigan, United States

  • Wake Forest University

    Winston-Salem, North Carolina, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

IL13-PE38QQR
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Nov 2000
Primary completion
31 Jul 2007
Completion
31 Jul 2007
Last update posted
14 Nov 2014
Registered enrollment
60
Registry id
NCT00024570
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.